ENGOT-EN20/GOG-3083/XPORT-EC-042 A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients (pts) with P53 wild-type, advanced or recurrent endometrial carcinoma (1246)

Vicky Makker,Ignace Vergote,Mansoor Mirza,Robert Coleman,Jose Alejandro Perez Fidalgo,Bradley Monk,Giorgio Valabrega,Brian Slomovitz,Toon Van Gorp,Kathleen Moore,Jalid Sehouli,David Cibula,Tally Levy,Gerasimos Aravantinos,Patricia Judson,Reshma Rangwala,Xulong Wang

doi:10.1016/j.ygyno.2023.06.155

Abstract

ENGOT-EN20/GOG-3083/XPORT-EC-042 A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients (pts) with P53 wild-type, advanced or recurrent endometrial carcinoma (1246)

Full Text